A number of approved medications , such as copyright and Semaglutide, fall under the incretin mimetic category . Primarily , these therapies work by mimicking the body's own hormones that impact blood sugar and encourage weight loss . While copyright is a brand name for managing type 2 diabetes

Sufferers struggling with obesity are often faced with limited and sometimes ineffective treatment options. However, a groundbreaking new medication, Semaglutide, is rapidly changing the landscape of weight loss. Approved by regulatory bodies for chronic weight management, Semaglutide acts as a